Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.

ABSTRACT: Although the survival of metastatic colorectal cancer (mCRC) patients has improved five-fold over the last century, CRC remains a significant global health burden. Impressive strides have been made in identifying new regimens, employing maintenance strategies to limit treatment toxicities, and combining multidisciplinary approaches to achieve cure in oligometastatic disease. Attempts at personalized integration of targeted agents have been limited by the ability to identify molecularly enriched patient populations most likely to benefit. In this review, we discuss novel therapeutics and regimens recently approved and in development for mCRC. In addition, we discuss using older agents in novel combination and maintenance strategies, and highlight evidence for implementing pharmacogenomic da

SUBMITTER: Hanna DL 

PROVIDER: S-EPMC7493705 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature